Stay updated with breaking news from Andre Uddin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Andre Uddin of Research Capital Corp thinks investors will want to own a piece of Theratechnologies going forward, since its pipeline of drug prospects is worth it. Uddin delivered a report on THTX to clients on Wednesday where he reiterated a Buy rating while lowering his target price to $3.50.
Knight Therapeutics Inc. (OTCPK:KHTRF) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Samira Sakhia - President and CEO Jeff Martens - Global VP of...
Medexus Pharmaceuticals Inc. (OTCQX:MEDXF) Q2 2023 Earnings Conference Call November 9, 2022 08:00 ET Company Participants Victoria Rutherford - Investor Relations, Adelaide Capital Ken...
Knight Therapeutics, Inc. (OTCPK:KHTRF) Q2 2022 Earnings Conference Call August 11, 2022, 8:30 am ET Company Participants Samira Sakhia - President & CEO Amal Khouri - CBO Arvind...
Medexus Pharmaceuticals Inc. (OTCQX:MEDXF) Q4 2022 Earnings Conference Call June 23, 2022 8:00 am ET Company Participants Ken d’Entremont - Chief Executive Officer Marcel Konrad - Chief...